An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases.
Over the years, the importance of receptor activator of nuclear factor κB ligand (RANKL) in bone physiology and pathophysiology has been thoroughly documented. Denosumab, also known as AMG 162, is a fully human monoclonal antibody against RANKL which is being studied in the treatment of metabolic, inflammatory, and malignant bone diseases. The purpose of this review is to analyze the potential role of denosumab in osteoporosis, rheumatoid arthritis, bone metastases and multiple myeloma.
Maldonado-Gonzales
Eduardo
E
Department of Pathophysiology, Medical University of Vienna, Vienna, Austria.
Pietschmann
Peter
P
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D015519:Bone Density / Q000187:drug effects / Q000276:immunology; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary; D001862:Bone Resorption / Q000188:drug therapy / Q000276:immunology; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000097:blood; D000069448:Denosumab; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology; D010010:Osteoclasts / Q000187:drug effects / Q000276:immunology; D010024:Osteoporosis / Q000188:drug therapy* / Q000276:immunology; D053245:RANK Ligand / Q000276:immunology* / Q000627:therapeutic use*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D053245:RANK Ligand; C505688:TNFSF11 protein, human; D000069448:Denosumab